CompanyGraph
At a glance
- Depends onMidstream position: 6 outgoing, 8 incoming connections
- PositionGross margin is 17.4%, lower than 95% of its Medical Devices peers (median 61%)
- Interpretations1 currently firing — 1
Sign in to view price data.
Sign inWhat the company actually pays, and whether its own cash supports it.
Dividends view
Yield
0.24%
Annual Rate
CNY 0.20Paid annual
Payout Ratio
95.8%High
Last Ex-Dividend
Jun 1, 2026
The reported statements, read against the company's own industry.
Financials view
Market Capitalization
5.69BCNY842.86M · vs all stocks (USD)
Trailing P/E
238.71xvs Medical Devices peers
Revenue (TTM)
454.82MCNY67.42M · vs all stocks (USD)
Profit Margin
4.69%vs Medical Devices peers
Beta
-0.0220xvs all stocks
52-Week Change
96.48%vs all stocks
Market Capitalization
5.69BCNY842.86M · vs all stocks (USD)
Enterprise Value
4.33BCNY642.06M · vs all stocks (USD)
Trailing P/E
238.71xvs Medical Devices peers
Price to Sales (TTM)
11.06xvs Medical Devices peers
Price to Book (MRQ)
6.54xvs Medical Devices peers
Enterprise to Revenue
9.52xvs Medical Devices peers
Enterprise to EBITDA
74.68xvs Medical Devices peers
Gross Margin
17.44%vs Medical Devices peers
Profit Margin
4.69%vs Medical Devices peers
Operating Margin
9.20%vs Medical Devices peers
Return on Assets (TTM)
1.47%vs Medical Devices peers
Return on Equity (TTM)
2.77%vs Medical Devices peers
Revenue (TTM)
454.82MCNY67.42M · vs all stocks (USD)
Revenue per Share (TTM)
6.69CNYUpdated Aug 8, 2026Quarterly Revenue Growth
-3.30%vs Medical Devices peers
Gross Profit (TTM)
67.63MCNY10.03M · vs all stocks (USD)
EBITDA (TTM)
24.95MCNY3.70M · vs all stocks (USD)
Net Income (TTM)
21.31MCNY3.16M · vs all stocks (USD)
Quarterly Earnings Growth (YoY)
42.90%vs Medical Devices peers
Operating Cash Flow (TTM)
60.76MCNY9.01M · vs all stocks (USD)
Levered Free Cash Flow (TTM)
36.74MCNY5.45M · vs all stocks (USD)
Trailing Annual Dividend Rate
0.2000CNYUpdated Aug 8, 2026Trailing Annual Dividend Yield
0.24%vs all stocks
Payout Ratio
95.75%vs Medical Devices peers
Revenue
458.28MCNYFY2025 · Dec 31, 2025Cost of Goods Sold
391.48MCNYFY2025 · Dec 31, 2025Gross Profit
66.80MCNYFY2025 · Dec 31, 2025Operating Income
18.64MCNY2.76M · vs all stocks (USD)
Pre-tax Income
22.89MCNYFY2025 · Dec 31, 2025Income Tax Expense
4.00MCNYFY2025 · Dec 31, 2025Net Income
18.89MCNYFY2025 · Dec 31, 2025EBIT
22.91MCNYFY2025 · Dec 31, 2025EBITDA (Income Statement)
63.59MCNYFY2025 · Dec 31, 2025Research & Development
9.74MCNYFY2025 · Dec 31, 2025Selling, General & Administrative
11.62MCNYFY2025 · Dec 31, 2025Other Operating Expenses
3.92MCNYFY2025 · Dec 31, 2025Non-operating Interest Income
2.44MCNYFY2025 · Dec 31, 2025Non-operating Interest Expense
18.83KCNYFY2025 · Dec 31, 2025EPS (Basic)
0.2778CNYFY2025 · Dec 31, 2025EPS (Diluted)
0.2778CNYFY2025 · Dec 31, 2025Basic Shares Outstanding
68.01MSharesFY2025 · Dec 31, 2025Diluted Shares Outstanding
68.01MSharesFY2025 · Dec 31, 2025Net Income from Continuing Operations
18.89MCNYFY2025 · Dec 31, 2025Preferred Stock Dividends
0.00CNYFY2025 · Dec 31, 2025Operating Cash Flow
33.58MCNYFY2025 · Dec 31, 2025Free Cash Flow
16.52MCNYFY2025 · Dec 31, 2025Cash & Cash Equivalents (End of Period)
78.18MCNYFY2025 · Dec 31, 2025Starting Profit (CF Statement)
18.89MCNYFY2025 · Dec 31, 2025Other Non-cash Items
-753.97KCNYFY2025 · Dec 31, 2025Change in Accounts Receivable (CF)
13.37MCNYFY2025 · Dec 31, 2025Change in Other Assets/Liabilities
2.07MCNYFY2025 · Dec 31, 2025Capital Expenditures
-17.06MCNYFY2025 · Dec 31, 2025Purchase of Investments
-1.24BCNYFY2025 · Dec 31, 2025Sale of Investments
1.13BCNYFY2025 · Dec 31, 2025Net Investing Cash Flow
-128.44MCNYFY2025 · Dec 31, 2025Common Dividends Paid
-20.37MCNYFY2025 · Dec 31, 2025Other Financing Charges
-617.86KCNYFY2025 · Dec 31, 2025Net Financing Cash Flow
-20.99MCNYFY2025 · Dec 31, 2025Shares Outstanding
68.00MSharesUpdated Aug 8, 2026Float Shares
20.60MSharesUpdated Aug 8, 2026% Held by Insiders
70.25%vs all stocks
% Held by Institutions
0.64%vs all stocks
Total Cash (MRQ)
406.99MCNY60.33M · vs all stocks (USD)
Total Cash per Share (MRQ)
5.99CNYUpdated Aug 8, 2026Total Debt (MRQ)
256.11KCNY37.96K · vs all stocks (USD)
Total Debt to Equity (MRQ)
0.0003xvs Medical Devices peers
Current Ratio (MRQ)
8.07xvs Medical Devices peers
Book Value per Share (MRQ)
11.31CNYUpdated Aug 8, 2026Total Assets
869.04MCNY128.82M · vs all stocks (USD)
Total Current Assets
573.74MCNYFY2025 · Dec 31, 2025Total Liabilities
108.02MCNYFY2025 · Dec 31, 2025Total Non-current Assets
295.30MCNYFY2025 · Dec 31, 2025Total Non-current Liabilities
16.51MCNYFY2025 · Dec 31, 2025Total Current Liabilities
91.51MCNYFY2025 · Dec 31, 2025Cash
78.17MCNYFY2025 · Dec 31, 2025Cash Equivalents
2.91MCNYFY2025 · Dec 31, 2025Cash & Cash Equivalents
81.08MCNYFY2025 · Dec 31, 2025Other Short-term Investments
337.80MCNYFY2025 · Dec 31, 2025Accounts Receivable
89.32MCNYFY2025 · Dec 31, 2025Inventory
41.76MCNYFY2025 · Dec 31, 2025Accounts Payable
60.18MCNYFY2025 · Dec 31, 2025Short-term Debt
254.58KCNYFY2025 · Dec 31, 2025Other Current Liabilities
568.18KCNYFY2025 · Dec 31, 2025Long-term Debt
0.00CNYFY2025 · Dec 31, 2025Common Stock (Book)
68.00MCNYFY2025 · Dec 31, 2025Retained Earnings
266.02MCNYFY2025 · Dec 31, 2025Total Shareholders' Equity
761.02MCNY112.81M · vs all stocks (USD)
52-Week Low
31.06CNYUpdated Aug 8, 202652-Week High
83.62CNYUpdated Aug 8, 202652-Week Change
96.48%vs all stocks
Beta
-0.0220xvs all stocks
50-Day MA
43.32CNYUpdated Aug 8, 2026200-Day MA
41.11CNYUpdated Aug 8, 2026Avg 10-Day Volume
7.06MSharesUpdated Aug 8, 2026Avg 30-Day Volume
2.78MSharesUpdated Aug 8, 2026Diluted EPS (TTM)
0.3100CNYUpdated Aug 8, 20261 interpretation currently present — each is a set of fired observations whose alignment reads as one structural pattern. Click an observation to see the numbers behind it.
Screen for these patternsIs this company financially stable?
MRQ Cash Elevated Relative To Total Debt With EBITDA And FCF Elevated Relative To Total Liabilities
Cash covers most of its debt, with earnings high against its liabilities.
Reads
An interpretation is present only while every observation it reads stays fired (score ≥ 70). It describes what the aligned readings show — never a verdict, never a prediction.
Shared structure with peers — never a ranking.
Relationships view
Structural observations derived from financial data, industry benchmarks, and supply chain position.
Peer Positioning
Gross margin is 17.4%, lower than 95% of its Medical Devices peers (median 61%)Significant
Gross margin: 0.17Industry median: 0.61Industry P5: 0.28Peers compared: 102
P/E ratio is 238.71×, higher than 95% of its Medical Devices peers (median 31.47×)Significant
P/E ratio: 238.71Industry median: 31.47Industry P95: 200.906Peers compared: 102
Debt-to-equity is 0×, lower than 95% of its Medical Devices peers (median 0.11×)Notable
Debt-to-equity: 0.00Industry median: 0.11Industry P5: 0.00Peers compared: 102
Supply Chain
Midstream position: 6 outgoing, 8 incoming connectionsNotable
Outgoing: 6.00Incoming: 8.00
High connectivity hub: 14 industry connectionsNotable
Total Connections: 14.00
Companies that share the same coordination system — how they create, deliver, or capture value.
Genfit S.A.
Tier 1ProductionApproval-Gated PipelineRuleRisk
R&G Pharmastudies Co. Ltd.
Tier 1ProductionApproval-Gated PipelineRuleSenseMaking
Chengdu Shengnuo Biotech Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Pharming Group N.V.
Tier 1ProductionApproval-Gated PipelineRule
Shouyao Holdings Beijing Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Gansu Longshenrongfa Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Luoxin Pharmaceuticals Group Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Solid Biosciences Inc.
Tier 1ProductionApproval-Gated PipelineRuleRisk
HK inno.N Corporation
Tier 1ProductionApproval-Gated PipelineRule
Replimune Group Inc.
Tier 1ProductionApproval-Gated PipelineRule
Companies that share active interpretations — structural patterns currently present in both stocks.
Jiangxi JDL Environmental Protection Co. Ltd.
1 interpretationMRQ Cash Elevated Relative To Total Debt With EBITDA And FCF Elevated Relative To Total Liabilities
King Slide Works Co., Ltd.
1 interpretationMRQ Cash Elevated Relative To Total Debt With EBITDA And FCF Elevated Relative To Total Liabilities
Butler National Corporation
1 interpretationMRQ Cash Elevated Relative To Total Debt With EBITDA And FCF Elevated Relative To Total Liabilities